Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites ATLANTA and SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- ...
MONTREAL, Feb. 25, 2025 /CNW/ - bioMérieux, a world leader in the field of in vitro diagnostics, has achieved a significant milestone with the Health Canada approval of the BIOFIRE ® SPOTFIRE ® ...
On September 9, 2025, Altesa BioSciences announced a partnership with bioMérieux to use the BIOFIRE SPOTFIRE respiratory diagnostic platform as the primary point-of-care tool in its upcoming Phase 2B ...
Altesa BioSciences and bioMérieux Announce Collaboration for Altesa's Upcoming Phase 2B COPD Clinical Trial PR Newswire ATLANTA and SALT LAKE CITY, Sept. 9, 2025 Study will begin enrollment in Q1 2026 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results